Navigation Links
ALS Therapy Development Institute, the World's Largest Non-Profit Biotech, Appoints Steve Perrin, Ph.D., as Chief Executive Officer
Date:5/1/2009

Board of Directors Also Appoints a New President and Adds A New Member

CAMBRIDGE, Mass., May 1 /PRNewswire-USNewswire/ -- Steve Perrin, Ph.D., was appointed chief executive officer and Maureen Lister was appointed president of the ALS Therapy Development Institute (ALS TDI) during the annual meeting of its Board of Directors. The two appointments come following the passing of Sean Scott, the Institute's previous president, due to complications from Lou Gehrig's disease (ALS) this past February.

"Simply put, the research and development program at ALS TDI is the most comprehensive one possible today. Under Steve's leadership, the ALS TDI research team has produced tangible results that all ALS community members can be proud of. In this dual capacity as both CEO and CSO, Steve will be able to continue to advance our shared mission on behalf of patients today," said Augie Nieto, chairman of the board of directors at ALS TDI and an ALS patient.

As chief executive officer and chief scientific officer at ALS TDI, Steve Perrin, Ph.D., will be responsible for ensuring the Institute continues to advance its mission to discover and develop effective therapeutics for ALS. ALS TDI executes the largest and most comprehensive therapeutic development effort in the world focused entirely on stopping amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease). ALS is a progressive neurodegenerative disease which affects at least 30,000 Americans at any given time. Dr. Perrin is an expert in the drug development process and has nearly two decades of experience in leading preclinical and translational research efforts.

Since coming to ALS TDI in 2007, Dr. Perrin has added new capabilities to the Institute's drug development pipeline, which now includes small molecules, gene therapy, protein biologics and stem cell projects. This multi-faceted approach is designed to meet the unmet medical need posed by ALS by
'/>"/>

SOURCE ALS Therapy Development Institute
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
2. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
3. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
4. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
5. Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability
6. Elekta Contract Provides Sisters of Mercy Health System Access to Leading Radiation Therapy Solutions
7. Varian Medical Systems Exhibits Latest Technologies and Products Designed to Improve Speed and Precision of Radiotherapy at ESTRO 2007
8. Elekta Displays Complete Volumetric Intensity Modulated Arc Therapy Solutions at ESTRO
9. Stem Cell Therapy to Skyrocket by 2017
10. Team demos safety of RNA therapy
11. First European IGRT School Takes Place for Radiotherapy Practitioners in UK
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Wisc. (PRWEB) May 21, 2013 ... parts distributor , will be exhibiting for the ... Advancement of Medical Instrumentation (AAMI) 2013 Conference and ... purchase, support, distribute, and manufacture healthcare technologies. This ... in Long Beach, California. , The three-day ...
(Date:5/21/2013)... NC (PRWEB) May 21, 2013 ... financial services company for clinical trials, announced today ... Spend Solutions, LLC. Clinverse’s ClinPay® FLS eClinical ... investigator payment process. SpendMD ™, Aggregate ... complete solution for tracking and reporting transfer of ...
(Date:5/21/2013)... Canada (PRWEB) May 21, 2013 ... is a strong push within the industry to ... and Manufacturing Organizations and pharma companies often means ... frames. , Microtablets, developed in collaboration with Sensidose ... effective outsourcing can bring products to market sooner. ...
(Date:5/21/2013)... , May 21, 2013  MacroGenics, Inc. today ... of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody ... the HER2 oncoprotein," will be presented at the ... Clinical Oncology during the Developmental Therapeutics - Immunotherapy ... 4:15 – 4:30 PM.  The presentation will describe ...
Breaking Biology Technology:Alpha Source, Inc. to Exhibit at the AAMI 2013 Conference and Expo 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
... 4, 2011 Palatin Technologies, Inc. (NYSE Amex: ... Phase 1 clinical trial of AZD2820, a subcutaneously-administered peptide ... therapy for the treatment of obesity. AZD2820 is a ... program with Palatin Technologies. Obesity is a ...
... SynCo Bio Partners B.V., one of the leading ... filling facility is again fully operational and SynCo has produced ... after the expansion of its Class A zone.   ... important milestone in SynCo,s strategy in supporting its clients with ...
...   Creabilis SA, a clinical stage ... and pain, announces today that Dr David Roblin has been ... extensive experience in the pharmaceutical industry in a career spanning ... several drugs to the market. He has held leadership roles ...
Cached Biology Technology:Palatin Announces Commencement of a Phase 1 Trial for Obesity Compound in Collaboration with AstraZeneca 2Palatin Announces Commencement of a Phase 1 Trial for Obesity Compound in Collaboration with AstraZeneca 3SynCo Bio Partners Expands the Class A Zone in its Aseptic Filling Facility 2Creabilis Appoints Dr David Roblin as Chief Medical Officer 2Creabilis Appoints Dr David Roblin as Chief Medical Officer 3
(Date:5/21/2013)... occur in the body, stem cells in the ... differentiating into mature immune cells that can fight ... deplete these cell populations, potentially leading to the ... Now, a team of researchers led by biologists ... found that, in mouse models, the molecule microRNA-146a ...
(Date:5/21/2013)... University researchers have developed a new method for ... holes in the cell surface. The technique could ... related biological fields. , Bulk electroporation a ... reversible nanopores in the cell membrane that are ... is an increasingly popular method of cell transfection. ...
(Date:5/21/2013)... new University of Michigan Water Center today awarded ... Great Lakes restoration and protection efforts. , The ... diverse projects, including efforts to track the remediation ... techniques to control non-native weedy plant invasions; study ... fish responses to restoration activities. , The grants ...
Breaking Biology News(10 mins):Keeping stem cells strong 2Single-cell transfection tool enables added control for biological studies 2U-M Water Center awards $570K in Great Lakes restoration grants 2U-M Water Center awards $570K in Great Lakes restoration grants 3U-M Water Center awards $570K in Great Lakes restoration grants 4
... The Potato Genome Sequencing Consortium (PGSC), an international ... countries, has released a draft sequence of the potato ... Richard Veilleux, professor of horticulture in the College ... a unique phureja type of potato variety that accelerated ...
... could enhance plants, seed oil content for food and ... Science under an exclusive commercial agreement with Michigan State ... that regulates oil accumulation in plant seed was licensed ... technology transfer office. The gene is a transcription factor ...
... German . , Necessity is the mother ... harsh conditions of snow cover. This remarkable newly-acquired behaviour was ... in Seewiesen and their colleagues in a cave in Hungary. ... it and showed little or no interest in flying into ...
Cached Biology News:Draft potato genome based on unique potato variety 2MSU licenses plant oil enhancement technology to BASF Plant Science 2Great tits eat bats in times of need 2